Many of Australia's top brokers have been busy adjusting their financial models and recommendations again. This has led to the release of a number of broker notes this week.
Three ASX shares that brokers have named as buys this week are listed below. Here's why their analysts are feeling bullish on them right now:
Image source: Getty Images
Breville Group Ltd (ASX: BRG)
According to a note out of Morgan Stanley, its analysts have retained their overweight rating and $36.50 price target on this home appliance manufacturer's shares. The broker is feeling confident that Breville will report solid earnings growth with its FY 2025 results later this month. And looking ahead, it believes any impact from US tariffs will be manageable. This is thanks to the company's options to offset them with pricing, product mix, and cost efficiencies. In addition, given favourable global coffee trends and its expansion into China, the broker thinks Breville is well-placed for growth over the medium term. The Breville share price is trading at $32.91 this afternoon.
Electro Optic Systems Holdings Ltd (ASX: EOS)
A note out of Bell Potter reveals that its analysts have retained their buy rating on this defence and space company's shares with an improved price target of $5.00. This follows the announcement of a major order valued at approximately $125 million from a European NATO member state for a 100kw class laser defence system. It highlights that the new laser counter drone capability was developed to address the urgent market need and emerging strategic requirement to defend against drone swarm attacks at an economical cost. Bell Potter believes this contract gives EOS a first mover advantage in a new counter UAS vertical and presents potential investors with a new angle to gain leverage to the emerging drone warfare thematic. Overall, it sees it as a significant win and a key driver of long-term growth. The EOS share price is fetching $4.39 at the time of writing.
Telix Pharmaceuticals Ltd (ASX: TLX)
Another note out of Bell Potter reveals that its analysts have retained their buy rating on this radiopharmaceuticals company's shares with a trimmed price target of $33.00. The broker acknowledges that 2025 has been tough operationally with a triple whammy of negative events. This includes the receipt of a complete response letter for Pixclara, the SEC investigation on prostate cancer therapies, and now an increase in operating expenses beyond market expectation. However, it feels that the share price weakness has created a buying opportunity for investors. Particularly given its belief that its Zircaix product is likely to receive US FDA approval later this month. The Telix share price is trading at $18.70 on Wednesday.
